Exelixis stock stabilises as cabozantinib developer prices offering
This article was originally published in Scrip
Executive Summary
Exelixis' stock stabilised on 9 August when it priced 30 million shares of common stock at $4.25 per share in an offering that included 10 million more shares than the company said it would sell earlier in the week (scripintelligence.com, 8 August 2012).